Don't think it says "fail", but definitely doesn't say 'success'
Market just says , no money to be made from vaccines for a long time if.
They will need to prioritise now. in the immunotherapies. The company does not earn enough to fund everything in the pipe.
Short to medium term its all adapt and medical devices.
No need to pump immunology for now, it is what it is.
Ann: Admedus Releases Results of HSV-2 Phase IIa Study, page-61
-
- There are more pages in this discussion • 290 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$12.49 |
Change
0.490(4.08%) |
Mkt cap ! $264.0M | |||
| Open | High | Low | Value | Volume |
| $12.11 | $12.49 | $11.50 | $155.8K | 13.16K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 175 | $11.81 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $12.49 | 77 | 1 |
View Market Depth
| Last trade - 16.10pm 27/09/2024 (20 minute delay) ? |
| AVR (ASX) Chart |